A Novel Tumor-Node-Metastasis (TNM) Staging System of Diffuse Malignant Peritoneal Mesothelioma Using Outcome Analysis of A Multi-Institutional Database

BACKGROUND: Currently, no tumor-node-metastasis (TNM) staging system exists for patients with diffuse malignant peritoneal mesothelioma (DMPM). The primary objective was to formulate a clinicopathological staging system through the identification of significant prognostic parameters. METHODS: Eight international institutions with prospectively collected data on patients who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy contributed to the registry. Two hundred ninety-four patients had complete clinicopathological data and formed the basis of this staging project. RESULTS: Peritoneal cancer index (PCI) was categorized into T-1 (PCI 1-10), T-2 (PCI 11-20), T-3 (PCI 21-30), and T-4 (PCI 30-39). Twenty-two patients had positive lymph nodes (N-1) and 12 patients had extra-abdominal metastases (M-1). The survival for patients with T-1 (PCI 1-10) N-0 M-0 was significantly superior to the other patients. This group of patients is therefore designated as Stage I. The survival of patients with T-2 (PCI 11-20) and T-3 (PCI 21-30), in absence of N-1 or M-1 disease, was similar. This group of patients was categorized as Stage II. The survival of patients with T-4 (PCI 30-39), N-1, and/or M-1 was similarly poor. This group of patients was therefore categorized as Stage III. Three prognostic factors were independently associated with survival in the multivariate analysis: histological subtype, completeness of cytoreduction, and the proposed TNM staging. The 5-year survival associated with Stage I, II, and III disease was 87%, 53%, and 29%, respectively. CONCLUSIONS: The proposed TNM staging system resulted in significant stratification of survival by stage when applied to the current multi-institutional registry data. Cancer 2011;117:1855-63. (C) 2010 American Cancer Society.